|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/19/14 Aurinia Pharmaceuticals Inc. 40FR12B/A 6/18/14 86:8.8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 40FR12B/A Amendment to Registration of Securities of a HTML 62K
Canadian Issuer -- SEA'34 §12(b)
2: EX-99.1 Miscellaneous Exhibit HTML 27K
11: EX-99.10 Miscellaneous Exhibit HTML 26K
12: EX-99.11 Miscellaneous Exhibit HTML 23K
13: EX-99.12 Miscellaneous Exhibit HTML 23K
14: EX-99.13 Miscellaneous Exhibit HTML 22K
15: EX-99.14 Miscellaneous Exhibit HTML 22K
16: EX-99.15 Miscellaneous Exhibit HTML 365K
17: EX-99.16 Miscellaneous Exhibit HTML 308K
18: EX-99.17 Miscellaneous Exhibit HTML 369K
19: EX-99.18 Miscellaneous Exhibit HTML 426K
20: EX-99.19 Miscellaneous Exhibit HTML 414K
3: EX-99.2 Miscellaneous Exhibit HTML 27K
21: EX-99.20 Miscellaneous Exhibit HTML 186K
22: EX-99.21 Miscellaneous Exhibit HTML 236K
23: EX-99.22 Miscellaneous Exhibit HTML 302K
24: EX-99.23 Miscellaneous Exhibit HTML 200K
25: EX-99.24 Miscellaneous Exhibit HTML 210K
26: EX-99.25 Miscellaneous Exhibit HTML 152K
27: EX-99.26 Miscellaneous Exhibit HTML 166K
28: EX-99.27 Miscellaneous Exhibit HTML 193K
29: EX-99.28 Miscellaneous Exhibit HTML 236K
30: EX-99.29 Miscellaneous Exhibit HTML 139K
4: EX-99.3 Miscellaneous Exhibit HTML 25K
31: EX-99.30 Miscellaneous Exhibit HTML 284K
32: EX-99.31 Miscellaneous Exhibit HTML 24K
33: EX-99.32 Miscellaneous Exhibit HTML 26K
34: EX-99.33 Miscellaneous Exhibit HTML 23K
35: EX-99.34 Miscellaneous Exhibit HTML 33K
36: EX-99.35 Miscellaneous Exhibit HTML 30K
37: EX-99.36 Miscellaneous Exhibit HTML 628K
38: EX-99.37 Miscellaneous Exhibit HTML 296K
39: EX-99.38 Miscellaneous Exhibit HTML 27K
40: EX-99.39 Miscellaneous Exhibit HTML 26K
5: EX-99.4 Miscellaneous Exhibit HTML 25K
41: EX-99.40 Miscellaneous Exhibit HTML 283K
42: EX-99.41 Miscellaneous Exhibit HTML 89K
43: EX-99.42 Miscellaneous Exhibit HTML 280K
44: EX-99.43 Miscellaneous Exhibit HTML 25K
45: EX-99.44 Miscellaneous Exhibit HTML 30K
46: EX-99.45 Miscellaneous Exhibit HTML 31K
47: EX-99.46 Miscellaneous Exhibit HTML 32K
48: EX-99.47 Miscellaneous Exhibit HTML 46K
49: EX-99.48 Miscellaneous Exhibit HTML 26K
50: EX-99.49 Miscellaneous Exhibit HTML 30K
6: EX-99.5 Miscellaneous Exhibit HTML 24K
51: EX-99.50 Miscellaneous Exhibit HTML 28K
52: EX-99.51 Miscellaneous Exhibit HTML 54K
53: EX-99.52 Miscellaneous Exhibit HTML 37K
54: EX-99.53 Miscellaneous Exhibit HTML 30K
55: EX-99.54 Miscellaneous Exhibit HTML 26K
56: EX-99.55 Miscellaneous Exhibit HTML 27K
57: EX-99.56 Miscellaneous Exhibit HTML 24K
58: EX-99.57 Miscellaneous Exhibit HTML 23K
59: EX-99.58 Miscellaneous Exhibit HTML 55K
60: EX-99.59 Miscellaneous Exhibit HTML 25K
7: EX-99.6 Miscellaneous Exhibit HTML 24K
61: EX-99.60 Miscellaneous Exhibit HTML 31K
62: EX-99.61 Miscellaneous Exhibit HTML 26K
63: EX-99.62 Miscellaneous Exhibit HTML 25K
64: EX-99.63 Miscellaneous Exhibit HTML 25K
65: EX-99.64 Miscellaneous Exhibit HTML 57K
66: EX-99.65 Miscellaneous Exhibit HTML 46K
67: EX-99.66 Miscellaneous Exhibit HTML 26K
68: EX-99.67 Miscellaneous Exhibit HTML 26K
69: EX-99.68 Miscellaneous Exhibit HTML 26K
70: EX-99.69 Miscellaneous Exhibit HTML 26K
8: EX-99.7 Miscellaneous Exhibit HTML 26K
71: EX-99.70 Miscellaneous Exhibit HTML 26K
72: EX-99.71 Miscellaneous Exhibit HTML 26K
73: EX-99.72 Miscellaneous Exhibit HTML 26K
74: EX-99.73 Miscellaneous Exhibit HTML 29K
75: EX-99.74 Miscellaneous Exhibit HTML 24K
76: EX-99.75 Miscellaneous Exhibit HTML 24K
77: EX-99.76 Miscellaneous Exhibit HTML 20K
78: EX-99.77 Miscellaneous Exhibit HTML 26K
79: EX-99.78 Miscellaneous Exhibit HTML 36K
80: EX-99.79 Miscellaneous Exhibit HTML 27K
9: EX-99.8 Miscellaneous Exhibit HTML 26K
81: EX-99.80 Miscellaneous Exhibit HTML 31K
82: EX-99.81 Miscellaneous Exhibit HTML 31K
83: EX-99.82 Miscellaneous Exhibit HTML 22K
84: EX-99.83 Miscellaneous Exhibit HTML 23K
85: EX-99.84 Miscellaneous Exhibit HTML 22K
86: EX-99.85 Miscellaneous Exhibit HTML 25K
10: EX-99.9 Miscellaneous Exhibit HTML 26K
| Prepared by R.R. Donnelley Financial -- EX-99.3 |
Exhibit 99.3
Form 52-109F1R
Certification of Refiled Annual Filings
This certificate is being filed on the same date that Aurinia Pharmaceuticals Inc. (the “issuer”) has refiled its annual financial statements for the year ended December 31, 2013.
I, STEPHEN W. ZARUBY, Chief Executive Officer of AURINIA PHARMACEUTICALS INC., certify the following:
| 1. | Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the “annual filings”) of the issuer for the financial year ended December 31, 2013. |
| 2. | No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings. |
| 3. | Fair presentation: Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings. |
| Date: | April 1, 2014 | |
| Signed: | “Stephen W. Zaruby” | |
| STEPHEN W. ZARUBY | ||
| Chief Executive Officer | ||
NOTE TO READER
In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of
| i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and |
| ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP. |
The issuer’s certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.
| This ‘40FR12B/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 6/19/14 | None on these Dates | ||
| Filed on: | 6/18/14 | |||
| 4/1/14 | ||||
| 12/31/13 | ||||
| List all Filings | ||||